Source-grounded facts extracted from Cadrenal Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
James J. Ferguson III resigned as Chief Medical Officer at Cadrenal Therapeutics, Inc..
“On July 7, 2026, James J. Ferguson III, Chief Medical Officer of Cadrenal Therapeutics, Inc. (the “Company”), advised the Board of Directors of the Company of his decision to resign from his position as Chief Medical Officer of the Company, effective July 31, 2026 (the “Separation Date”).”
Quang X. Pham was appointed as interim Chief Financial Officer and interim Principal Accounting Officer at Cadrenal Therapeutics, Inc..
“Effective immediately after Mr. Szot's termination, the Company appointed Quang X. Pham, its Chief Executive Officer, as interim Chief Financial Officer and interim Principal Accounting Officer, to serve until a permanent Chief Financial Officer is appointed.”
Matthew K. Szot changed role as Chief Financial Officer at Cadrenal Therapeutics, Inc..
“On May 28, 2026, Cadrenal Therapeutics, Inc. (the "Company") and Matthew K. Szot mutually agreed to his transition from the role of Chief Financial Officer, effective May 28, 2026.”
Cadrenal Therapeutics, Inc. reported the quarter ended March 31, 2026 results: net income $2.5 million.
“Cadrenal reported a net loss of $2.5 million for the quarter ended March 31, 2026”
Cadrenal Therapeutics, Inc. issued 37,143 shares of Common Stock of warrant to H.C. Wainwright & Co., LLC for exercise price of $5.625 per share.
“Shares. The Placement Agent Warrants will have substantially the same terms as the Series B-1 Warrants, except that the Placement Agent Warrants will have an exercise price of $5.625 per share, which is equal to 125% of the exercise price of the New Warrants. 1 Terms of the New Warrants The New Warrants will be immediately exercisable at an exercise price of”
Cadrenal Therapeutics, Inc. issued 571,430 shares of Common Stock of warrant to Holder of Existing Warrants for exercise price of $4.50 per share.
“of the Existing Warrants agreed to exercise for cash the Existing Warrants to purchase up to an aggregate of 571,430 shares of Common Stock, at the adjusted exercise price of $4.50 per share (reduced from the initial exercise price of $16.50 per share). The offer and resale of the shares of Common Stock underlying the Existing Warrants (the “Existing Warrant”
Cadrenal Therapeutics, Inc. entered into Inducement Agreement with a holder of Existing Warrants valued at approximately $2.5 million (effective 2026-03-31).
“On March 31, 2026, Cadrenal Therapeutics, Inc. (the “Company”) entered into a warrant inducement letter agreement (the “Inducement Agreement”) with a holder (the “Holder”) of the Company’s warrants to purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), issued in a private placement offering that closed on November 4, 2024 (the “Existing Warrants”).”
Cadrenal Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2025 results: net income $3.0 million for the quarter ending December 31, 2025.
“Cadrenal Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release that included financial information for the fiscal year ended December 31, 2025.”
Cadrenal Therapeutics, Inc. entered into Purchase Agreement with certain investors named on the signature pages thereto valued at approximately $2.2 million (effective 2025-12-15).
“On December 15, 2025, Cadrenal Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with certain investors named on the signature pages thereto.”
Cadrenal Therapeutics, Inc. issued 414,748 shares of Common Stock of warrant to certain investors named on the signature pages for $10.60 per share.
“attached as Exhibit 4.1 to this Current Report on Form 8-K, which is incorporated herein by reference. Terms of the Common Warrants The Common Warrants have an exercise price of $10.60 per share. The shares of Common Stock issuable upon the exercise of the Common Warrants are referred to as the “Common Warrant Shares.” The Common Warrants are”
Cadrenal Therapeutics, Inc. issued 207,374 shares of common stock to certain investors named on the signature pages for $10.85 per share.
“private placement, unregistered warrants (the “Common Warrants”) to purchase up to 414,748 shares of Common Stock (collectively, the “Offering”). The offering price per Share is $10.85. The Shares are being offered pursuant to an effective shelf registration statement on Form S-3 (File No. 333-277835) (the “Registration Statement”), a base prospectus included”
Cadrenal Therapeutics, Inc. entered into Asset Purchase Agreement with Veralox Therapeutics Inc. valued at $200,000 (effective 2025-12-10).
“On December 10, 2025, Cadrenal Therapeutics, Inc., a Delaware corporation (the “Company”) entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Veralox Therapeutics Inc., a Delaware corporation (“Seller”)”
Douglas Losordo was terminated as Chief Medical Officer at Cadrenal Therapeutics, Inc..
“On February 4, 2025, the Company terminated its employment relationship with its Chief Medical Officer, Douglas Losordo, on a mutual amicable basis.”
James J. Ferguson III was appointed as Chief Medical Officer at Cadrenal Therapeutics, Inc..
“On February 4, 2025, Cadrenal Therapeutics, Inc. (the “Company”) entered into an employment agreement with James J. Ferguson III (the “Employment Agreement”), effective as of February 5, 2025 (the “Effective Date”), to employ Dr. Ferguson as the Company’s Chief Medical Officer.”
Cadrenal Therapeutics, Inc. entered into At the Market Offering Agreement with H.C. Wainwright & Co., LLC valued at $5,143,730 (effective 2024-03-11).
“On March 11, 2024, Cadrenal Therapeutics, Inc., a Delaware corporation, (the “Company”), entered into an At the Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”), as sales agent to sell shares of the Company’s common stock”
Cadrenal Therapeutics, Inc. reported financial results for the fiscal year ended December 31, 2023.
“On March 11, 2024, Cadrenal Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release that included financial information for the fiscal year ended December 31, 2023.”
Cadrenal Therapeutics, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
“March 5, 2024, the Company received written notification from Nasdaq granting the Company's request for a 180-day extension or until September 3, 2024 to regain compliance with the Rule. Compliance is generally achieved by meeting the minimum bid price of $1.00 per share (the “Price Requirement”) for a minimum of 10 consecutive business days. However, the Staff may, in its discretion, require a Company to satisfy the applicable Price Requirement for a period in excess of 10 consecutive business days, but generally no more than 20 consecutive business days, before determining that the Company h”
Jeffrey Cole was appointed as Chief Operating Officer at Cadrenal Therapeutics, Inc..
“On February 6, 2024, Cadrenal Therapeutics, Inc. (the “Company”) entered into an offer letter agreement (the “Offer Letter”) with Jeffrey Cole describing the terms of his employment as the Company’s Chief Operating Officer.”
Cadrenal Therapeutics, Inc. shareholders approved Ratification of the appointment of WithumSmith+Brown, P.C. as the Company’s independent registered public accounting firm for the year ending December 31, 2023 at the 2023-10-20 meeting.
“Proposal 2 . Ratification of the appointment of WithumSmith+Brown, P.C. as the Company’s independent registered public accounting firm for the year ending December 31, 2023 . The stockholders ratified and approved the appointment of WithumSmith+Brown, P.C. as the Company’s independent registered public accounting firm for the year ending December 31, 2023 based on the votes listed below: Votes For Votes Against Abstentions Broker Non-Votes 11,126,433 10,899 192 0”
Cadrenal Therapeutics, Inc. shareholders approved Election of Directors at the 2023-10-20 meeting.
“Proposal 1 . Election of Directors . The following two (2) individuals were elected as Class I directors, to serve until the Company’s 2026 Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified with the following votes: Name of Director Votes For Withheld Broker Non-Votes Quang Pham 10,183,242 8,560 945,722 Glynn Wilson 10,139,612 52,190 945,722”
Cadrenal Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“September 6, 2023, Cadrenal Therapeutics, Inc. (the “Company”) received a letter from The Nasdaq Stock Market (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) (the “Rule”), requiring listed securities to maintain a minimum bid price of $1.00 per share because the Company’s closing bid price for the last 30 consecutive business days was below $1.00 per share. The notification received has no immediate effect on the Company’s continued listing on the Nasdaq Capital Market, subject to the Company’s compliance with the other continued listing requiremen”
Cadrenal Therapeutics, Inc. reported financial results for the quarter ended June 30, 2023.
“issued a press release that included financial information for the fiscal quarter ended June 30, 2023.”
Robert Lisicki was appointed as Class II Director at Cadrenal Therapeutics, Inc..
“appointed Robert Lisicki to serve as a Class II director of the Company”
Cadrenal Therapeutics, Inc. entered into Engagement Agreement with H.C. Wainwright & Co., LLC (effective 2023-07-12).
“Pursuant to a letter agreement dated July 12, 2023 (the “Engagement Agreement”), H.C. Wainwright & Co., LLC (“HWC”) acted as placement agent for the Private Placement.”
Cadrenal Therapeutics, Inc. entered into Registration Rights Agreement with the Investor (effective 2023-07-12).
“In connection with the Private Placement, the Company has entered into a registration rights agreement (the “Registration Rights Agreement”) with the Investor, dated July 12, 2023”
Cadrenal Therapeutics, Inc. entered into Purchase Agreement with an institutional accredited investor valued at approximately $7.5 million (effective 2023-07-12).
“On July 12, 2023, Cadrenal Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an institutional accredited investor (the “Investor”)”
Cadrenal Therapeutics, Inc. reported preliminary financial results for the fiscal quarter ended March 31, 2023.
“On May 10, 2023, Cadrenal Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release that included financial information for the fiscal quarter ended March 31, 2023.”
Cadrenal Therapeutics, Inc. entered into Underwriting Agreement with Boustead Securities, LLC (as representative of the underwriters) valued at Gross proceeds of $7,000,000 from sale of 1,400,000 shares at $5.00 per share; Representative's Warr (effective 2023-01-19).
“On January 19, 2023, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Boustead Securities, LLC, as representative of the underwriters (the “Representative”), a form of which was previously filed as an exhibit to the Company’s registration statement on Form S-1, as amended (File No. 333-267562), which was declared effective by the Securities and Exchange Commission (the “Commission”) on January 19, 2023 (the “Registration Statement”).”
Douglas Losordo was appointed as Chief Medical Officer at Cadrenal Therapeutics, Inc..
“Upon completion of the IPO, we entered into an employment agreement with each of Matthew Szot, the Company’s Chief Financial Officer, and Douglas Losordo, the Company’s Chief Medical Officer.”
Matthew Szot was appointed as Chief Financial Officer at Cadrenal Therapeutics, Inc..
“Upon completion of the IPO, we entered into an employment agreement with each of Matthew Szot, the Company’s Chief Financial Officer, and Douglas Losordo, the Company’s Chief Medical Officer.”
Steven Zelenkofske was appointed as Class III Director at Cadrenal Therapeutics, Inc..
“Steven Zelenkofske was appointed as a Class III director”
John Murphy was appointed as Class II Director at Cadrenal Therapeutics, Inc..
“John Murphy was appointed as a Class II director”
Glynn Wilson was appointed as Class I Director at Cadrenal Therapeutics, Inc..
“Glynn Wilson was appointed as a Class I director”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.